Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Introduction Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, is approved in the USA to reduce risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus (T2DM) and established CV disease, based on EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial...

Full description

Bibliographic Details
Main Authors: Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, Lael Cragin, Sarah B Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/9/1/e001313.full

Internet

https://drc.bmj.com/content/9/1/e001313.full

Similar Items